Skip to content

Lymph Node Response and Survival Outcomes to Immunochemotherapy in Gastric and Esophagogastric Junction Cancer: A Multicenter Real-World Study

Lymph Node Response and Survival Outcomes to Immunochemotherapy in Gastric and Esophagogastric Junction Cancer: A Multicenter Real-World Study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500104269
Enrollment
Unknown
Registered
2025-06-13
Start date
2025-06-30
Completion date
Unknown
Last updated
2025-06-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric cancer

Interventions

Sponsors

The First Medical Center of Chinese PLA General Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1.Age 20 to 80 years, regardless of gender; ?2.Histologically confirmed diagnosis of adenocarcinoma; ?3.Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1; 4.?American Society of Anesthesiologists (ASA) physical status classification of I to III; 5.?Underwent radical surgery with D2 lymphadenectomy; 6.Underwent neoadjuvant chemotherapy with or without immunotherapy, completing >=2 cycles of treatment; 7.No distant metastasis (M0) confirmed preoperatively.

Exclusion criteria

Exclusion criteria: 1.Received preoperative radiotherapy or targeted therapy. Regimen unconfirmed; ?2.Presence of multiple gastric lesions (multifocal tumors); 3.Preoperative detection of distant metastasis (M1 stage) or intraoperative findings of peritoneal carcinomatosis/positive peritoneal cytology; 4.History of other malignancies within 5 years (excluding non-melanoma skin cancer); 5.Underwent emergency surgery or palliative resection; 6.Missing critical clinical data (e.g., unspecified lymph node station details in pathology reports, unrecorded preoperative treatment plans) precluding analysis.

Design outcomes

Primary

MeasureTime frame
Recurrence-free survival;

Secondary

MeasureTime frame
Overall survival;Metastasis rates of lymph node groups No.1 to No.12;Pathological complete response;ypN0 rate;Surgical complication;

Countries

China

Contacts

Public ContactZhang Chaojun

?The First Medical Center of Chinese PLA General Hospital

13276047818@163.com+86 186 0031 7036

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026